The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.
Dizal Pharmaceutical's Zegfrovy has taken the EGFR inhibitor class into new territory after hitting the mark in a phase 3 trial as a first-line treatment for non-small cell lung cancer (NSCLC) with ...
SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates ...
The once-daily oral drug improves patients’ lives while maintaining early, durable, and central nervous system responses, ...
We read with interest the results of the HARMONi-6 trial by Zhiwei Chen and colleagues,1 which showed that ivonescimab plus chemotherapy improved progression-free survival versus tislelizumab plus ...
A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...
Zipalertinib showed a 35% overall response rate in EGFR exon 20 mutated NSCLC, with notable CNS activity and a favorable safety profile. NeoADAURA trial highlighted the feasibility of neoadjuvant EGFR ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results